EBOS Group Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

EBOS Group wird ein jährliches Gewinn- und Umsatzwachstum von 7% bzw. 1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 6.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13% betragen.

Wichtige Informationen

7.0%

Wachstumsrate der Gewinne

6.3%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	26.1%
Wachstumsrate der Einnahmen	1.0%
Zukünftige Eigenkapitalrendite	13.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

ASX:EBO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	12,864	333	349	424	10
6/30/2026	12,283	300	320	394	11
6/30/2025	11,688	261	277	411	11
6/30/2024	13,189	272	229	348	N/A
3/31/2024	12,932	264	218	342	N/A
12/31/2023	12,674	257	206	336	N/A
9/30/2023	12,456	255	250	364	N/A
6/30/2023	12,237	253	293	391	N/A
3/31/2023	11,933	243	258	347	N/A
12/31/2022	11,629	233	222	303	N/A
9/30/2022	11,182	218	191	276	N/A
6/30/2022	10,734	203	159	249	N/A
3/31/2022	10,267	198	175	278	N/A
12/31/2021	9,800	194	190	306	N/A
9/30/2021	9,502	190	203	302	N/A
6/30/2021	9,203	185	216	298	N/A
3/31/2021	9,123	180	222	276	N/A
12/31/2020	9,043	174	228	254	N/A
9/30/2020	8,904	168	214	241	N/A
6/30/2020	8,766	163	200	229	N/A
3/31/2020	8,288	157	161	191	N/A
12/31/2019	7,810	152	121	153	N/A
9/30/2019	7,370	145	103	136	N/A
6/30/2019	6,930	138	84	119	N/A
3/31/2019	6,909	136	74	115	N/A
12/31/2018	6,888	134	64	110	N/A
9/30/2018	6,937	136	84	136	N/A
6/30/2018	6,987	137	104	162	N/A
3/31/2018	7,016	134	N/A	172	N/A
12/31/2017	6,927	129	N/A	179	N/A
9/30/2017	6,998	126	N/A	157	N/A
6/30/2017	7,271	127	N/A	137	N/A
3/31/2017	7,023	122	N/A	169	N/A
12/31/2016	7,396	127	N/A	217	N/A
9/30/2016	7,033	123	N/A	214	N/A
6/30/2016	6,797	122	N/A	215	N/A
3/31/2016	6,057	110	N/A	169	N/A
12/31/2015	5,957	109	N/A	141	N/A
9/30/2015	5,641	101	N/A	129	N/A
6/30/2015	5,343	93	N/A	118	N/A
3/31/2015	5,868	100	N/A	112	N/A
12/31/2014	5,608	92	N/A	91	N/A
9/30/2014	5,182	84	N/A	93	N/A
6/30/2014	5,345	85	N/A	106	N/A
3/31/2014	4,598	72	N/A	89	N/A
12/31/2013	3,746	58	N/A	69	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EBODas prognostizierte Gewinnwachstum (7% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: EBODie Erträge des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Australian (12.5% pro Jahr).

Hohe Wachstumserträge: EBODie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: EBODie Einnahmen des Unternehmens (1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Australian (5.7% pro Jahr).

Hohe Wachstumseinnahmen: EBODie Einnahmen des Unternehmens (1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EBODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13%).

EBOS Group Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased to AU$31.66

Price target raised to AU$25.70

Recent updates

EBOS Group Limited Announces the Retirement of Peter Williams as Director

Final dividend of NZ$0.64 announced

EBOS Group Limited Announces Final Dividend, Payable on 18 September 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Chief Financial Officer Changes

Insider recently sold AU$4.9m worth of stock

First half dividend of NZ$0.60 announced

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 20% undervalued

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.

Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk

EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit

EBOS Not to Proceed with Acquisition in Animal Care Segment

EBOS Not to Proceed with Acquisition in Animal Care Segment

Now 21% undervalued

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended June 30, 2023, Payable on 29 September, 2023

Now 21% undervalued

Upcoming dividend of NZ$0.60 per share at 3.0% yield

Ebos Group Limited Announces Dividend, Payable on 29 September 2023

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorates as stock falls 17%

Now 26% undervalued after recent price drop

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited to Report Q2, 2023 Results on Feb 22, 2023

EBOS Group Limited Announces the Appointment of Mark Bloom as an Independent Director, Effective 16 September 2022

Upcoming dividend of NZ$0.51 per share

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 30 September, 2022

Upcoming dividend of NZ$0.49 per share

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended December 31, 2021, Payable on March 18, 2022

Ebos Group Limited Announces Resignation of Nick Dowling as Director

Independent Director recently bought AU$55k worth of stock

Price target increased to AU$31.66

EBOS Group Limited Announces Supplementary Dividend for the Six Months Ended June 30, 2021, Payable on Sept. 24, 2021

Upcoming dividend of NZ$0.48 per share

EBOS Group Limited (EBOS) acquired Sentry Medical.

Full year 2021 earnings released: EPS AU$1.13 (vs AU$1.01 in FY 2020)

EBOS Group Limited (NZSE:EBO) acquired Pioneer Medical Limited for AUD 40 million.

Price target raised to AU$25.70

First half 2021 earnings released: EPS AU$0.57 (vs AU$0.51 in 1H 2020)

Revenue beats expectations

EBOS Group Limited (NZSE:EBO) acquired Vet Distribution Business of Clifford Hallam Healthcare Pty Ltd for AUD 9.2 million.

EBOS Group Limited (NZSE:EBO) acquired CH2 Vet for AUD 9.2 million.

EBOS Group Limited, Annual General Meeting, Oct 19, 2021

New 90-day high: AU$27.92

New 90-day high: AU$25.25

EBOS Group Limited (NZSE:EBO) entered into an agreement to acquire Cryomed Aesthetics Pty Limited for AUD 14.1 million.

New 90-day high: AU$23.26

New 90-day high - AU$21.38

Full year earnings released - EPS AU$1.01

New 90-day low - AU$20.00

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken